Journal: ESC Heart Failure

Article Title: Biomarker prognostication across Universal Definition of Heart Failure stages

doi: 10.1002/ehf2.14071

Figure Lengend Snippet: Influential variables predicting cardiovascular death or heart failure hospitalization. Patients were categorized as Universal Definition of Heart Failure (A) Stage A/B and (B) Stage C/D. hxcopd, history of chronic obstructive pulmonary disease; Hxdm2, history of diabetes mellitus; Log ET‐1, log‐transformed endothelin 1; log ET‐1, log‐transformed endothelin‐1; log Gal3, log‐transformed galectin‐3; log hs‐CRP, log‐transformed high‐sensitivity C‐reactive protein; log hs‐cTnI, log‐transformed high‐sensitivity cardiac troponin I; Log NTproBNP, log‐transformed N ‐terminal prohormone of B‐type natriuretic peptide; log ST2, log‐transformed soluble ST2; log suPAR, log‐transformed soluble urokinase plasminogen activator receptor.

Article Snippet: Utilizing all available information, including past history and history at the time of angiography, results of invasive evaluations (including filling pressures and left ventricular angiograms), along with concentrations of NT‐proBNP (Siemens Diagnostics, Newark, DE) and high‐sensitivity cardiac troponin I (hs‐cTnI, Abbott Diagnostics, Abbott Park, IL), study participants were categorized into the 2021 Universal Definition and Classification of Heart Failure Stages ( Table ): Stage A : Persons with no past or present history of HF, no symptoms of dyspnoea, no structural cardiac changes with a left ventricular ejection fraction ≥50%, no history of acute myocardial infarction, significant aortic or mitral valve disease or history of valvular surgery, no implantable cardioverter defibrillator placement, normal filling pressures (pulmonary capillary wedge pressure <15 mmHg, left ventricular end‐diastolic pressure < 13 mmHg), NT‐proBNP < 300 ng/L, and hs‐cTnI <99th percentile (male ≥34 ng/L; female ≥16 ng/L) Stage B : Persons with no past or present history of HF and no symptoms of dyspnoea, but with any of the following: abnormal cardiac structural changes, elevated filling pressures or abnormal biomarker concentrations (NT‐proBNP ≥ 300 ng/L), and hs‐cTnI ≥99th percentile (male ≥34 ng/L; female ≥16 ng/L).

Techniques: Transformation Assay